Oral Peptide Formats: Capsules, Troches and the Bioavailability Question

Oral formats are studied in spite of intestinal absorption, not because of it — uptake is genuinely poor. They have a place because some research questions only require the peptide to reach the intestinal lumen, and because troches and capsules get around the gut barrier by quite different routes. The literature reports systemic bioavailability for unmodified peptides taken by mouth in solution at below 1%, so any oral study needs to state up front whether its question is a local or a systemic one. Below we look at what degrades peptides as they move through the digestive tract, what enteric films, counter-ion choices and sublingual troches change about that, and how to reason about an oral study design. All of this concerns laboratory reference material.

Four obstacles between a capsule and the bloodstream

1. Stomach acid. Somewhere between pH 1.5 and 3.5, backbone hydrolysis is accelerated and any secondary structure comes apart. A sequence sensitive to acid may be largely destroyed within the hour it spends there.
2. Luminal proteases. Pepsin acts first; then, in the duodenum, pancreatic trypsin, chymotrypsin and carboxypeptidases, enzymes whose entire purpose is cleaving peptide bonds. As far as they are concerned, a research peptide is indistinguishable from dietary protein.
3. The brush border and the epithelial layer. Whatever emerges from the lumen intact then meets aminopeptidases fixed to the enterocyte surface, and must cross an epithelium whose tight junctions exclude hydrophilic molecules much smaller than any peptide.
4. The liver. Whatever is absorbed travels in the portal blood and is metabolised on its way through the liver before it can reach the general circulation.

Put end to end, these four steps are why an unmodified peptide taken orally shows bioavailability measured in tenths of a percent. The instructive exception is the oral semaglutide tablet, which achieved a reported 0.4-1% only by co-formulating the peptide with the permeation enhancer SNAC at roughly one hundred times the peptide's own mass — and which is an approved medicine rather than research material.

Local questions versus systemic ones

Some of the most frequently requested oral peptides are of interest precisely for their activity within the digestive tract rather than elsewhere in the body. BPC-157 capsules and KPV capsules illustrate this well. BPC-157 was originally identified as part of a protein present in gastric juice, and a great deal of the rodent literature relies on mucosal models of the gut where the lumen and its lining are the compartment being investigated. KPV — the three-residue C-terminal piece of α-MSH — has been studied in colitis models in which the epithelium is itself the tissue of interest.

For that kind of design, low systemic absorption is closer to a feature than a defect: it keeps exposure where the question lies and cuts down confounding systemic signal. That logic does not transfer to a study asking whether a peptide acts on a brain receptor or a tendon, where an oral format is simply the wrong tool. BPC-157 capsules vs BPC-157 works the format comparison through for a single molecule.

Differences between the formats

A troche is not a capsule that dissolves slowly

Troches are formulated to dissolve in contact with the mucosa under the tongue — an epithelium that is thin, non-keratinised, and drained by veins going to the systemic circulation instead of the portal vein, which means the fraction absorbed there never passes through the liver first. That brings two complications. The molecular-size ceiling familiar from nasal delivery applies here too, with uptake dropping away sharply beyond about 1,000 Da; and saliva keeps carrying dissolved peptide down the oesophagus, so anything swallowed is back in the digestive tract facing all its barriers. Oxytocin troches, at 1,007 Da, sit almost exactly at that ceiling, whereas AOD-9604 troches at 1,815 Da are above it — and there the stated rationale rests on buccal and local exposure rather than on efficient systemic absorption.

What a capsule figure really represents

Suppose a protocol calls for a capsule holding 500 mcg of peptide.

1. Systemic equivalent at 1% bioavailability: multiply by 0.01 and 5 mcg reaches the circulation intact. It is that 5 mcg, not the 500 mcg printed on the capsule, that should be compared with an injected reference arm.
2. At 0.3% — nearer to what is reported for unmodified peptides with no absorption enhancer — 0.003 × 500 leaves 1.5 mcg.
3. For a local question, calculate the luminal concentration instead: 500 mcg dispersed in an assumed 250 mL of intestinal fluid is 2 mcg/mL, about 1.4 µM for a peptide of 1,420 Da such as BPC-157 — a number you can build a cell-culture experiment around.
4. Against a vial: 500 mcg is 0.2 mL of a 2.5 mg/mL solution made from a 5 mg vial, delivered with essentially no proteolytic loss — a difference of 100- to 300-fold in systemic mass for the same nominal amount.

Simply stating which of these four numbers a protocol means removes most of the ambiguity that surrounds oral peptide work.

Handling and storage

• Troches and capsules are solid dosage forms that include excipients. They are not meant to be reconstituted, and should not be opened and dissolved unless the study explicitly calls for it, since the matrix or coating is part of what is specified.
• Store them cool, dark and dry. Humidity is the main hazard: HPMC and gelatin shells soften and adhere to each other, and troche bases lose firmness above roughly 25 °C.
• Do not refrigerate capsules unless they are sealed, because the condensation that forms as they warm up is worse for them than room-temperature storage in a jar with desiccant.
• A certificate for an oral format should state both the purity of the peptide and how much peptide each unit contains; request both, as how to read a COA explains.

Frequent errors

• Comparing an oral label mass with a parenteral one. These are not the same quantity — in systemic terms they differ by two or three orders of magnitude.
• Assuming an enteric film raises systemic bioavailability. It delivers more intact peptide to the intestine, but the epithelial barrier and hepatic first pass are unchanged.
• Formulating a large peptide as a troche and describing the design as sublingual delivery when the majority of the material is in fact swallowed.
• Emptying capsules in order to make a solution. The fill includes excipients never characterised for solution work, so you cannot know the resulting concentration; use a freeze-dried vial whenever a defined concentration is required.

Our complete oral range is in the peptide capsules and oral collection.